Sobetirome

What is Sobetirome?

Sobetirome — originally designated GC-1 — is a small-molecule thyromimetic (~314 Da diphenylmethane, structurally unrelated to peptides) that selectively activates the thyroid hormone receptor β (TRβ) subtype with roughly 10-fold preference over TRα. It was designed in Thomas Scanlan and John Baxter's collaborative program at UCSF/OHSU and reported in Chiellini et al., Chemistry & Biology 1998, as one of the first genuinely subtype-selective thyroid hormone analogs. The TRβ selectivity was engineered specifically to capture the hepatic lipid-lowering effects of thyroid hormone (a TRβ-dominant tissue) while sparing the cardiac and skeletal-muscle TRα-mediated effects that make actual thyroid hormone excess dangerous. Sobetirome is included in this atlas as a reference entry — it is unambiguously not a peptide, but it appears often enough in metabolic-therapeutics conversations adjacent to GLP-1/GIP peptides, tesamorelin (visceral fat), and MASLD pharmacotherapy that a clarifying page is useful. The clinically relevant TRβ agonist to know about today is resmetirom (Rezdiffra), approved by the FDA in March 2024 as the first therapy for MASH with fibrosis — a mechanistic descendant of the GC-1 template. Sobetirome itself was tested through Phase 2 for hypercholesterolemia and paused when the broader thyromimetic class ran into cardiac and cartilage safety concerns (eprotirome's Phase 3 failure is the emblematic case). It was subsequently repurposed at OHSU into a brain-penetrant amide prodrug — Sob-AM2 (also called sobetiramide) — designed to be hydrolyzed by fatty-acid amide hydrolase (FAAH) inside the brain to release active sobetirome selectively in the CNS. This CNS-selective prodrug approach is the basis for investigational programs in X-linked adrenoleukodystrophy (X-ALD), MCT8 deficiency (Allan-Herndon-Dudley syndrome), and multiple sclerosis remyelination. Autobahn Therapeutics carried a related next-generation thyromimetic (ABX-002) into clinical development. As of 2026 sobetirome and Sob-AM2 remain investigational; neither is approved for any indication.

What Sobetirome Is Investigated For

Sobetirome / GC-1 matters as a foundational scientific template, not as a therapeutic in current clinical use. The strongest legacy is mechanistic: Chiellini and colleagues' 1998 paper established that TRβ-selective agonism could dissociate the hepatic lipid-lowering effects of thyroid hormone from the cardiac/musculoskeletal TRα effects that limit thyroid-hormone excess as a therapy. Every subsequent TRβ-selective thyromimetic — resmetirom (Madrigal, approved for MASH 2024), VK2809 (Viking), eprotirome (KB2115, Phase 3 failure), ASC41 (Ascletis), and Autobahn Therapeutics' ABX-002 — traces its design logic to GC-1. Direct clinical development of sobetirome for hypercholesterolemia was paused when the broader thyromimetic class ran into class-level safety concerns (cardiac, cartilage, bone) in late-stage trials of eprotirome and others. The active current story is the OHSU program (Scanlan and colleagues) that reformulated sobetirome as Sob-AM2 — a CNS-selective amide prodrug hydrolyzed by fatty-acid amide hydrolase (FAAH) in brain tissue to release active drug preferentially in the CNS. Preclinical data in X-linked adrenoleukodystrophy (X-ALD), MCT8 deficiency, and MS demyelination has been substantial; human clinical translation is still early. This page exists as an atlas-adjacent reference because sobetirome comes up frequently in metabolic-peptide discussions (tesamorelin visceral fat, GLP-1-class MASLD effects) and because 'GC-1' is often incorrectly listed among peptide compounds in gray-market catalogs and biohacker forums — it is not a peptide, it is not sold as a legitimate consumer product anywhere, and self-administration of investigational thyromimetics carries genuinely serious cardiac and metabolic risks.

History & Discovery

Sobetirome originated in a UCSF-OHSU collaboration led by Thomas Scanlan (medicinal chemistry) and John Baxter (thyroid hormone endocrinology) in the mid-1990s, building on the idea that the two thyroid hormone receptor isoforms — TRα and TRβ — had different tissue distributions that might allow subtype-selective ligands to dissociate hepatic from cardiac thyroid-hormone effects. Grazia Chiellini, then a postdoctoral fellow with Scanlan, led the medicinal chemistry that produced GC-1 (glossily short for 'Grazia Compound 1' in laboratory shorthand). The compound was reported in Chiellini et al., Chemistry & Biology, June 1998 — a paper that has since been widely cited as the foundational proof of concept for TRβ-selective drug design. Karo Bio, a Swedish biotechnology company focused on nuclear-receptor drug discovery, acquired rights and advanced sobetirome through preclinical toxicology and into human Phase 1 pharmacology. Phase 1 studies demonstrated the expected LDL-lowering profile without proportional cardiac stimulation, and a Phase 2 hypercholesterolemia study was initiated. In parallel, Karo Bio developed a follow-on TRβ agonist — eprotirome (KB2115) — that reached a Phase 3 lipid-lowering trial called the AKKA study in the early 2010s. The AKKA study was terminated in 2012 after dog toxicology data showed cartilage damage at exposures being evaluated in humans. This class-level safety signal — combined with earlier cardiac-safety concerns and the parallel commercial success of statins and PCSK9 inhibitors in the same therapeutic space — effectively ended enthusiasm for TRβ agonists in lipid-lowering, and sobetirome development for hypercholesterolemia was shelved. A parallel academic reinterpretation of the molecule then reshaped its trajectory. At Oregon Health & Science University (OHSU), Scanlan and colleagues (including Skyler Jenkins, Meredith Hartley, and others) developed Sob-AM2 — the amide prodrug of sobetirome that is hydrolyzed by fatty-acid amide hydrolase (FAAH) in brain tissue to release active drug preferentially in the CNS. Meinig et al. 2017 in ACS Chemical Neuroscience established the FAAH-prodrug strategy, and subsequent papers extended the approach to X-linked adrenoleukodystrophy (X-ALD, where the therapeutic goal is inducing ABCD2 to compensate for defective ABCD1) and MCT8 deficiency / Allan-Herndon-Dudley syndrome (where the goal is bypassing the defective brain thyroid hormone transporter). Autobahn Therapeutics (San Diego), founded in 2018 with connections to the OHSU program, has advanced ABX-002 — a related next-generation thyromimetic — into clinical development. The broader TRβ-selective thyromimetic class continued to mature independently: resmetirom (Madrigal Pharmaceuticals) received FDA approval in March 2024 as Rezdiffra for MASH with fibrosis — the first regulatory success in the entire class, and a direct descendant of the GC-1 template three decades after Chiellini's original paper.

How It Works

Thyroid hormone (T3) makes the liver burn fat and lower LDL cholesterol — but it also speeds up the heart, weakens bones, and shrinks muscle at doses high enough to matter for fat loss. Sobetirome is a small molecule designed to hit only the specific thyroid receptor (TRβ) that lives in the liver, while mostly ignoring the receptor (TRα) that drives the heart and bone effects. In theory this gives you the metabolic upside of thyroid hormone without the classic dangers of taking too much of it. In practice, the thyromimetic drug class has repeatedly hit safety walls in late-stage trials, and sobetirome itself never crossed the finish line for its original lipid-lowering indication. Its second life is as a brain-penetrant prodrug (Sob-AM2) for rare CNS diseases where restoring thyroid-hormone signaling inside the brain — without flooding the rest of the body — is the therapeutic goal.

Sobetirome (GC-1, 3,5-dimethyl-4-(4′-hydroxy-3′-isopropylbenzyl)-phenoxyacetic acid) is a diphenylmethane thyromimetic that binds thyroid hormone receptor β (TRβ) with high affinity (Ki roughly 21 nM) and modestly lower affinity for TRα (Ki roughly 400 nM), giving it a ~10-fold TRβ selectivity that was the design rationale. TR receptors are nuclear receptors that heterodimerize with retinoid X receptor (RXR) and bind thyroid hormone response elements (TREs) in the promoters of target genes, driving transcription of the standard thyroid-hormone-responsive gene set (SHBG, cholesterol-7-α-hydroxylase, low-density lipoprotein receptor upregulation, sterol regulatory element-binding protein 2, mitochondrial biogenesis pathways). TRβ is the dominant TR isoform in liver, pituitary, and hypothalamus; TRα predominates in cardiac muscle, skeletal muscle, and bone. This differential distribution is the mechanistic basis for TRβ-selective drug design: activating TRβ selectively should engage the hepatic lipid-lowering program (LDL reduction, hepatic triglyceride mobilization, cholesterol-to-bile-acid conversion) while sparing the cardiac and skeletal effects that make thyrotoxicosis dangerous. In practice, sobetirome at effective lipid-lowering doses lowered LDL cholesterol by 20-30% in Phase 1/2 studies without proportional increases in heart rate or SHBG that would signal thyrotoxicosis. Development was paused following broader class safety concerns rather than sobetirome-specific failures. The subsequent successful thyromimetic (resmetirom) added additional selectivity refinements and a MASH-focused indication where hepatic thyroid-hormone signaling is more central than in general dyslipidemia. The Sob-AM2 prodrug is the amide (as opposed to the parent acid) of sobetirome. Amide prodrugs have improved blood-brain barrier permeability due to reduced polarity, and they are activated to the parent acid by fatty-acid amide hydrolase (FAAH), an enzyme with substantially higher activity in CNS than in peripheral tissues. This produces a CNS-selective exposure profile: measurable brain sobetirome concentrations from Sob-AM2 dosing with meaningfully lower peripheral exposure than would be achieved by giving the same amount of parent sobetirome. In X-ALD, the therapeutic hypothesis is that Sob-AM2 can activate brain TRβ enough to induce ABCD2 (a peroxisomal ABC transporter that partially compensates for the ABCD1 defect responsible for X-ALD) without producing peripheral thyromimetic side effects. In MCT8 deficiency, the hypothesis is that Sob-AM2 can bypass the defective MCT8 transporter (which normally moves T3 into brain tissue) by supplying TRβ activation via a different chemical route.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Sobetirome:

• 01Whether Sob-AM2 delivers meaningful clinical benefit in X-linked adrenoleukodystrophy — the mechanistic case (ABCD2 induction via TRβ) is strong but human efficacy data is still forthcoming.
• 02Whether the CNS-selective delivery of Sob-AM2 is sufficient in patients with MCT8 deficiency (Allan-Herndon-Dudley syndrome) to correct the neurological phenotype — a rare-disease indication where the therapeutic window and long-term outcomes are still being defined.
• 03Long-term safety of chronic CNS-selective thyromimetic exposure — the FAAH-prodrug approach reduces peripheral exposure, but chronic CNS TRβ activation over years has not been characterized in humans.
• 04Whether next-generation thyromimetics (ABX-002, VK2809) that share the GC-1 design rationale but differ in specific selectivity and PK profiles produce meaningfully different safety-efficacy trade-offs than sobetirome — differences at the compound level rather than the class level.
• 05The cartilage-safety signal from the eprotirome Phase 3 termination — whether sobetirome and Sob-AM2 share this liability at clinically relevant exposures, or whether their specific selectivity profiles mitigate it.
• 06Whether MASLD/MASH indications, now dominated by resmetirom, could accommodate a sobetirome-derived agent — commercial and clinical rationale is limited given resmetirom's approved-first-in-class position, but a MASH-plus-lipid-lowering profile might differentiate.
• 07Whether the biohacker-market use of 'GC-1' for fat loss produces measurable harm at population scale — anecdotal reports of cardiac symptoms exist but no systematic surveillance data has been reported.

Forms & Administration

Sobetirome is not commercially available in any FDA-approved formulation. In academic and industry research, it has been administered orally (rodent and clinical Phase 1/2 studies) as sobetirome free acid or hydrochloride at doses ranging from micrograms/kg (mouse) to milligram-scale (human Phase 1). Sob-AM2 is administered orally in preclinical studies and in the early-phase clinical programs derived from the OHSU work. There is no approved dose, no legitimate outpatient pharmacy channel, and no wellness-appropriate formulation. Products sold as 'GC-1' or 'sobetirome' by research-chemical vendors are not verified for identity, purity, or sterility, and the biohacker use of thyromimetics for fat loss is not supported by any clinical evidence and carries documented cardiac and musculoskeletal risks. Any legitimate access is through enrollment in a sponsored clinical trial of Sob-AM2 or a next-generation thyromimetic.

Common Questions

Who Sobetirome Is NOT For

Drug & Supplement Interactions

Sobetirome has meaningful pharmacodynamic and pharmacokinetic interactions to consider even though most are theoretical given the absence of a licensed product. Thyroid hormone replacement (levothyroxine, liothyronine) will produce additive TR activation and additive HPT-axis suppression; concurrent use is not appropriate outside protocol-defined study conditions. Antithyroid agents (methimazole, propylthiouracil) counter thyroid hormone synthesis but do not block sobetirome's direct TRβ activation. Warfarin and other narrow-therapeutic-index anticoagulants can be sensitive to thyromimetic-driven changes in vitamin K-dependent clotting factor turnover; close INR monitoring would be required if sobetirome were used clinically. Statins, PCSK9 inhibitors, and bempedoic acid produce lipid-lowering effects that overlap with sobetirome's mechanism; in the historical clinical program, these were expected to be additive rather than synergistic. Beta-blockers may mask thyromimetic-driven tachycardia and are sometimes co-administered in thyroid-hormone-excess management. CNS-active drugs are of particular interest for Sob-AM2 development because FAAH is inhibited by the endocannabinoid-modulating drug class (FAAH inhibitors are in development for pain and psychiatric indications); concurrent FAAH inhibition would meaningfully reduce Sob-AM2's CNS activation. As a specialty investigational drug, any actual clinical use should have all concurrent medications disclosed to the study team.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions